Manager, Business and Community Relations, Faculty for Mathematics and Natural Sciences, University of Oslo

Joined February 2017
Photos and videos
Eva S. Dugstad retweeted
31 Oct 2023
Det norske kreftvaksineselskapet sikrer seg avlesing i første halvdel av 2024 for INITIUM-studien. via @MedWatchNews medwatch.no/nyheter/legemidl…
1
24
1,079
Eva S. Dugstad retweeted
25 Oct 2023
Som tidligere annonsert så kommer @HellandAslaug i podkasten tirsdag - & nå kan vi melde at CMO Jens Bjørheim i @ultimovacs også blir med. Tema er NIPU-dataene og hva de betyr for kreftpasienter, og hva selskapet tenker videre nå. Send oss spørsmål:)
1
2
19
1,335
Eva S. Dugstad retweeted
21 Oct 2023
Oral session 15:15 at Salamanca Aud. @HellandAslaug #ESMO23 LBA99 First survival data from the NIPU trial: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant #mesothelioma
1
4
46
3,162
Eva S. Dugstad retweeted
20 Oct 2023
Ultimovacs has reported positive phase II overall survival data with its #cancervaccine candidate UV1 in #mesothelioma. BioStock spoke with Director Medical Affairs @EllingsenEspen to better understand the significance of these results. #biotech biostock.se/en/2023/10/ultim…

5
26
1,365
Eva S. Dugstad retweeted
Great news from Ultimovacs!
17 Oct 2023
First randomized phase 2 data with UV1 #cancervaccine - positive results in malignant #mesohelioma #ESMO23 @ultimovacs 🙌
1
11
1,020
Eva S. Dugstad retweeted
Gratulerer!
17 Oct 2023
Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma bit.ly/3QiYABc
2
2
47
20,792
Eva S. Dugstad retweeted
17 Oct 2023
Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma bit.ly/3QiYABc

9
16
95
41,773
Eva S. Dugstad retweeted
12 Oct 2023
Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma, Demonstrating Sustained Long-Term Overall Survival in Patients Treated with UV1 Cancer Vaccine: No confirmed patient deaths in cohort 1 between the 3-year and 4-year follow-up bit.ly/48Rrb7E
4
36
4,834
Eva S. Dugstad retweeted
26 Sep 2023
26 Sep 2023
Ny podkast ute - den lengste på en lang stund! Takk for besøk av Jens Bjørheim og Espen Basmo Ellingsen fra @ultimovacs Vi har snakket om legemiddelutvikling, kreftvaksineutvikling, INITIUM-studien & NIPU-studien - & svart på mange gode lytterspørsmål soundcloud.com/user-97220871…
1
7
873
Spennende jobb for deg som vil gjøre en forskjell: jobbnorge.no/en/available-jo…

23
Eva S. Dugstad retweeted
21 Aug 2023
We are looking forward to our Q2 2023 presentation tomorrow at 14:00 CEST. Questions to the management can be submitted throughout the event or by email to IR@ultimovacs.com Tune in to the webcast here: channel.royalcast.com/hegnar… #biotech #Q2_2023 #earnings

4
11
851
Vi tok debatten, realfagskrisen! Vi har en rekrutteringskrise til realfagene. Jan Tore Sanner mente at dette er den viktigste debatten ila Arendalsuka. Hvordan skal vi klare å bekle det fremtidige arbeidslivet innenfor fornybar energi, Ikt, helseteknologi mm.
1
78
Eva S. Dugstad retweeted
Want to learn more about our CEO? Read the portrait interview with Carlos de Sousa in @Finansavisen this Sat July 8 ☀️ #SummerReading #biotech #CEO #CancerResearch #Immunotherapy finansavisen.no/helse/2023/0…

3
5
997
Viktig tema i dagens verden! m.facebook.com/events/293111…

9
Eva S. Dugstad retweeted
28 Jun 2023
Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results @CCR_AACR bit.ly/3CQk8gV

1
3
16
1,638
Spennende jobb på Farmasøytisk institutt: Associate Professor in Pharmaceutics (247419) | University of Oslo (jobbnorge.no)

44
Eva S. Dugstad retweeted
22 Jun 2023
👋 Come join us for Investor Days in #Stavanger and #Trondheim in August! 📅 #Meet_the_Team
1
5
621